20. Treatment of patients with Glanzmann’s thrombasthenia who present with severe bleeding episodes is __________.

17. Which constituent of the peripheral zone contain glycoproteins responsible for bloodgroup specificity (ABO), tissue compatibility [human leukocyte antigen (HLA)], and plateletantigenicity?

24. Uremia is a __________ platelet disorder.

11. The prolonged bleeding time and abnormal platelet adhesion seen in vWD is due to the lack of __________.

33. In the process of aggregation, fibrinogen binds to the calcium complex of platelet membrane __________.

48. The P1A1 antigen is found in __________ of the normal population.

38. All of the following are effective in aggregating platelets in vitro except:

48. The P1A1 antigen is found in __________ of the normal population.

35. Platelets will not aggregate in the absence of membrane __________.

57. What is the coagulation factor assigned as factor VII?